vs

Side-by-side financial comparison of Empire State Realty Trust, Inc. (ESRT) and Kiniksa Pharmaceuticals International, plc (KNSA). Click either name above to swap in a different company.

Kiniksa Pharmaceuticals International, plc is the larger business by last-quarter revenue ($202.1M vs $190.3M, roughly 1.1× Empire State Realty Trust, Inc.). Kiniksa Pharmaceuticals International, plc runs the higher net margin — 7.0% vs 1.6%, a 5.5% gap on every dollar of revenue. On growth, Kiniksa Pharmaceuticals International, plc posted the faster year-over-year revenue change (65.0% vs 5.7%). Over the past eight quarters, Kiniksa Pharmaceuticals International, plc's revenue compounded faster (59.1% CAGR vs 0.2%).

Empire State Realty Trust is a leading real estate investment trust that owns, manages, and operates a portfolio of premium commercial, residential, and retail properties primarily in the New York City metropolitan area, including the iconic Empire State Building. It serves corporate tenants, retail partners, and residential occupants, focusing on sustainable property operations and long-term asset value growth.

Kiniksa Pharmaceuticals International plc is a global biopharmaceutical firm focused on discovering, developing and commercializing targeted therapies for patients with unmet medical needs, primarily in autoimmune, inflammatory and rare disease segments. It operates across major markets including North America, Europe and Asia, advancing a pipeline of clinical-stage and approved treatment candidates.

ESRT vs KNSA — Head-to-Head

Bigger by revenue
KNSA
KNSA
1.1× larger
KNSA
$202.1M
$190.3M
ESRT
Growing faster (revenue YoY)
KNSA
KNSA
+59.3% gap
KNSA
65.0%
5.7%
ESRT
Higher net margin
KNSA
KNSA
5.5% more per $
KNSA
7.0%
1.6%
ESRT
Faster 2-yr revenue CAGR
KNSA
KNSA
Annualised
KNSA
59.1%
0.2%
ESRT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESRT
ESRT
KNSA
KNSA
Revenue
$190.3M
$202.1M
Net Profit
$3.0M
$14.2M
Gross Margin
89.6%
Operating Margin
15.5%
9.8%
Net Margin
1.6%
7.0%
Revenue YoY
5.7%
65.0%
Net Profit YoY
-73.7%
259.8%
EPS (diluted)
$0.20
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESRT
ESRT
KNSA
KNSA
Q1 26
$190.3M
Q4 25
$199.2M
$202.1M
Q3 25
$197.7M
$180.9M
Q2 25
$191.3M
$156.8M
Q1 25
$180.1M
$137.8M
Q4 24
$197.6M
$122.5M
Q3 24
$199.6M
$112.2M
Q2 24
$189.5M
$108.6M
Net Profit
ESRT
ESRT
KNSA
KNSA
Q1 26
$3.0M
Q4 25
$32.2M
$14.2M
Q3 25
$13.6M
$18.4M
Q2 25
$11.4M
$17.8M
Q1 25
$15.8M
$8.5M
Q4 24
$18.8M
$-8.9M
Q3 24
$22.8M
$-12.7M
Q2 24
$28.6M
$-3.9M
Gross Margin
ESRT
ESRT
KNSA
KNSA
Q1 26
Q4 25
89.6%
Q3 25
88.8%
Q2 25
88.1%
Q1 25
87.0%
Q4 24
85.4%
Q3 24
82.1%
Q2 24
88.7%
Operating Margin
ESRT
ESRT
KNSA
KNSA
Q1 26
15.5%
Q4 25
17.8%
9.8%
Q3 25
19.9%
13.3%
Q2 25
18.4%
12.9%
Q1 25
14.3%
9.6%
Q4 24
21.7%
-15.7%
Q3 24
22.7%
-8.6%
Q2 24
20.8%
-0.1%
Net Margin
ESRT
ESRT
KNSA
KNSA
Q1 26
1.6%
Q4 25
16.1%
7.0%
Q3 25
6.9%
10.2%
Q2 25
6.0%
11.4%
Q1 25
8.8%
6.2%
Q4 24
9.5%
-7.3%
Q3 24
11.4%
-11.3%
Q2 24
15.1%
-3.6%
EPS (diluted)
ESRT
ESRT
KNSA
KNSA
Q1 26
$0.20
Q4 25
$0.11
$0.18
Q3 25
$0.05
$0.23
Q2 25
$0.04
$0.23
Q1 25
$0.05
$0.11
Q4 24
$0.07
$-0.11
Q3 24
$0.08
$-0.18
Q2 24
$0.10
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESRT
ESRT
KNSA
KNSA
Cash + ST InvestmentsLiquidity on hand
$68.8M
$414.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8B
$567.6M
Total Assets
$4.4B
$763.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESRT
ESRT
KNSA
KNSA
Q1 26
$68.8M
Q4 25
$132.7M
$414.1M
Q3 25
$154.1M
$352.1M
Q2 25
$94.6M
$307.8M
Q1 25
$187.8M
$268.3M
Q4 24
$385.5M
$243.6M
Q3 24
$421.9M
$223.8M
Q2 24
$535.5M
$218.8M
Stockholders' Equity
ESRT
ESRT
KNSA
KNSA
Q1 26
$1.8B
Q4 25
$1.1B
$567.6M
Q3 25
$1.0B
$535.4M
Q2 25
$1.0B
$495.0M
Q1 25
$1.0B
$457.5M
Q4 24
$1.0B
$438.4M
Q3 24
$1.0B
$437.0M
Q2 24
$1.0B
$435.1M
Total Assets
ESRT
ESRT
KNSA
KNSA
Q1 26
$4.4B
Q4 25
$4.5B
$763.6M
Q3 25
$4.1B
$712.3M
Q2 25
$4.1B
$661.1M
Q1 25
$4.1B
$599.3M
Q4 24
$4.5B
$580.6M
Q3 24
$4.4B
$555.3M
Q2 24
$4.4B
$542.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESRT
ESRT
KNSA
KNSA
Operating Cash FlowLast quarter
$53.9M
Free Cash FlowOCF − Capex
$53.3M
FCF MarginFCF / Revenue
26.4%
Capex IntensityCapex / Revenue
10.0%
0.3%
Cash ConversionOCF / Net Profit
3.80×
TTM Free Cash FlowTrailing 4 quarters
$136.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESRT
ESRT
KNSA
KNSA
Q1 26
Q4 25
$249.1M
$53.9M
Q3 25
$105.3M
$33.7M
Q2 25
$26.7M
$28.1M
Q1 25
$83.1M
$22.3M
Q4 24
$260.9M
$18.8M
Q3 24
$102.8M
$-2.2M
Q2 24
$37.1M
$5.2M
Free Cash Flow
ESRT
ESRT
KNSA
KNSA
Q1 26
Q4 25
$50.6M
$53.3M
Q3 25
$72.8M
$33.0M
Q2 25
$-55.1M
$27.9M
Q1 25
$41.1M
$22.2M
Q4 24
$88.0M
$18.6M
Q3 24
$-65.1M
Q2 24
$19.5M
FCF Margin
ESRT
ESRT
KNSA
KNSA
Q1 26
Q4 25
25.4%
26.4%
Q3 25
36.8%
18.2%
Q2 25
-28.8%
17.8%
Q1 25
22.8%
16.1%
Q4 24
44.5%
15.2%
Q3 24
-32.6%
Q2 24
10.3%
Capex Intensity
ESRT
ESRT
KNSA
KNSA
Q1 26
10.0%
Q4 25
99.6%
0.3%
Q3 25
16.5%
0.4%
Q2 25
42.8%
0.1%
Q1 25
23.4%
0.1%
Q4 24
87.5%
0.2%
Q3 24
84.1%
0.0%
Q2 24
9.3%
0.0%
Cash Conversion
ESRT
ESRT
KNSA
KNSA
Q1 26
Q4 25
7.74×
3.80×
Q3 25
7.72×
1.83×
Q2 25
2.35×
1.58×
Q1 25
5.27×
2.61×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESRT
ESRT

Rental revenue (1)$166.1M87%
Observatory revenue$18.5M10%
Other revenue and fees$4.1M2%
Lease termination fees$1.4M1%
Third-party management and other fees$277.0K0%

KNSA
KNSA

Segment breakdown not available.

Related Comparisons